
Médica Hematóloga. Hospital Privado Universitario de Cordoba. IUCBC. @SAHematologia #BMT #CART #quality #cellulartherapy
Joined April 2019
- Tweets1.2K
- Following344
- Followers529
- Likes1.1K
What is the right duration of antibiotic therapy after hematopoietic cell transplantation?
In this expert discussion, Diego R. Hijano, MD, MSc, Gabriela Marón, MD, MSc, and Fareed Khawaja, MBBS, review emerging clinical evidence, evolving guidelines, and future research directions surrounding antibiotic de-escalation in transplant recipients.
Tune in: ow.ly/HgZe5101mH2
Ana Lisa Basquiera retweeted
Un placer compartir con el Dr. Caeiro y la Dra. Clavijo un simposio sobre la primera recaída en mieloma múltiple.
🔬 MajesTEC-3: dara+ tec abre nuevas perspectivas.
Un cambio de paradigma: del control de la enfermedad hacia la cura funcional y, eventualmente, tratamientos finitos
Ana Lisa Basquiera retweeted
Desde julio iniciamos en @hcmquintela el tratamiento con células CART anti CD19 en el contexto del ensayo clínico liderado por @perezscremini Estamos orgullosos de poder hacer llegar a los pacientes adultos este tratamiento desde el Hospital Universitario @fmedoficial @Udelaruy
Ana Lisa Basquiera retweeted
What happens in the bone marrow clonal dynamics during sepsis? We studied by looking at emergency hematopoiesis in the ICU setting 👇@ClevelandClinic @Yale #CHIP @aamdsif @MDSFoundation @olisaogbue
Ana Lisa Basquiera retweeted
En el mes de setiembre la Unidad Académica de Hematología @CatedraHemato realizó el 1er Trasplante Autólogo de Progenitores Hematopoyéticos en @hcmquintela en el marco del subprograma de TPH con @ASSEHMaciel @FNR_Uruguay Destacamos la importancia del trabajo interdisciplinario
Ana Lisa Basquiera retweeted
Daratumumab in immune-mediated thrombotic thrombocytopenic purpura: emerging evidence for plasma cell–targeted therapy
tandfonline.com/doi/full/10.…
Ana Lisa Basquiera retweeted
Relapse is a challenge after allogeneic transplantation in FLT3-ITD AML. A large German registry study examines FLT3 inhibitor maintenance after transplant, highlighting real-world outcomes with sorafenib and other FLT3 inhibitors.
doi.org/10.3324/haematol.202…
Ana Lisa Basquiera retweeted
Really excited to share the first comprehensive study of germline DDX41 in MDS undergoing transplantation in @BloodPortfolio .
Grateful to Coleman Lindsley, germline brain Chris Reilly @DanaFarber and whole team from @CIBMTR 🙏❤️
ashpublications.org/blood/ar…
Ana Lisa Basquiera retweeted
Teclistamab densitization of donor-specific antibodies in aplastic anemia before haploHCT
Spoiler alert: it works, and yes, lower doses were used 😉
Our paper is out in Early View | @Haematologica
haematologica.org/newsletter…
Soluble BCMA Defines Spatial Phenotypes and Prognosis in Newly Diagnosed Multiple Myeloma ashpublications.org/blood/ar…
Ana Lisa Basquiera retweeted
This study found that ≥10% FEV1 decline affected ~48% of #alloHSCT recipients and was the strongest predictor of post-transplant mortality. Mortality risk remained elevated even after FEV1 recovery. Read: astctjournal.org/article/S26…
Ana Lisa Basquiera retweeted
Prognostic impact of variant allele frequency in intensively treated patients with NPM1-mutated AML: a PETHEMA study
ashpublications.org/blood/ar…
Ana Lisa Basquiera retweeted
Impact of healthcare setting on survival in adults with acute lymphoblastic leukemia in Latin America: insights from a large multinational cohort - The Lancet Regional Health – Americas thelancet.com/journals/lanam… 🇦🇷🇧🇷🇨🇱
Ana Lisa Basquiera retweeted
Proud to see @AnnaSureda5 on stage at #ISHL 2026 in Cologne, Germany 🇩🇪. The only Spaniard 🇪🇸 presenting in the International Symposium on Hodgkin Lymphoma #lymsm @sehh_es @geltamo
📊 New Infographic on ASTCT Nucleus: Geriatric assessment can help identify patient vulnerabilities, predict outcomes, and guide personalized care for older adults undergoing transplantation and cellular therapy. Explore key insights, implementation strategies, and expert recommendations for integrating geriatric assessment into clinical practice.
🔗 astct.org/Nucleus/Article/in…
Ana Lisa Basquiera retweeted
Laura donó células para salvar la vida de otra persona en el mundo 🌎
El Día Mundial del Donante de Médula Ósea se celebra cada año con el objetivo de agradecer a los donantes. Es una oportunidad para crear conciencia sobre la importancia de inscribirse en el Registro Nacional de Donantes de Células Progenitoras Hematopoyéticas (CPH).
El Registro argentino forma parte de la World Marrow Donor Association (WMDA), una red conformada por los Registros de 63 países. Así, una persona que necesita un trasplante puede encontrar un donante compatible sin importar dónde se encuentre.
¿Querés ser parte de la red? El primer paso es inscribirse 💛
Si tenés entre 18 y 40 años y gozás de buena salud, podés hacerlo donando sangre (tenés que pesar más de 50kg) o con un hisopado bucal ✅
Encontrá los centros habilitados 👉🏻 argentina.gob.ar/salud/mapam…
#DonáCélulas #WMDD
Yi Lin, MD, PhD, describes the science behind a phase 1 study of anitocabtagene autoleucel, a CAR T cell that deploys a CAR with a novel synthetic antigen-binding domain, in patients with multiple myeloma.
Learn more about the science behind the study in the editorial “Anito-cel for Multiple Myeloma”: nej.md/4hF5Gxj
Proud to share our latest publication from the Argentine GATMO-TC network @SAHematologia on allogeneic transplantation for Chronic Myeloid Leukemia in the TKI era. 🇦🇷
rdcu.be/BqEwdfFxiHWa
@SpringerNature
#CML #AlloHCT #BloodCancer #BMT #Hematology
Among children with high-risk B-cell acute lymphoblastic leukemia, two cycles of blinatumomab led to a higher 4-year event-free survival than two cycles of chemotherapy (83.0% vs. 70.3%), with a lower risk of serious infection. Full phase 3 AIEOP-BFM ALL 2017 trial results: nej.md/4dBfwOk
Editorial: Blinatumomab — A New Standard of Care in Acute Lymphoblastic Leukemia nej.md/3UWmKWP

ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia." The graph shows event-free survival. The trial name, AIEOP-BFM ALL 2017, is in parentheses after the title. The NEJM identity sits at the bottom.





























